☆ 4.8 Review

An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH

JOURNAL OF HEPATOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。
Review Gastroenterology & Hepatology

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review

Zobair M. Younossi et al.

Summary: A comprehensive meta-analysis was conducted to assess the global and regional prevalence, incidence, and mortality of non-alcoholic fatty liver disease (NAFLD). The results showed that the global prevalence of NAFLD is 30% and increasing, highlighting the need for urgent and comprehensive strategies to raise awareness and address NAFLD on local, regional, and global levels.

HEPATOLOGY (2023)

添加到收藏夹
Article Gastroenterology & Hepatology

Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression

Adrien Guillot et al.

Summary: This study investigates the hepatic immune microenvironment in chronic liver diseases using transcriptomic and histological methods. The findings suggest that the progression of NAFLD/NASH and primary sclerosing cholangitis is characterized by loss of parenchymal areas, accumulation of ductular cells, and infiltration of immune cells.

HEPATOLOGY (2023)

添加到收藏夹
Article Gastroenterology & Hepatology

Rational combination therapy for NASH: Insights from clinical trials and error

Vlad Ratziu et al.

Summary: Non-alcoholic steatohepatitis (NASH) is at the early stages of therapeutic development, with the prevailing opinion that combination therapy will be crucial for its treatment. However, developing combination therapies poses multiple challenges, such as predicting their added benefits over monotherapies and meeting regulatory requirements. Well-designed combination development programs could be essential to avoid further failures and ensure access to treatment for NASH patients.

JOURNAL OF HEPATOLOGY (2023)

添加到收藏夹
Article Cell Biology

An autocrine signaling circuit in hepatic stellate cells underlies advanced fibrosis in nonalcoholic steatohepatitis

Shuang Wang et al.

Summary: Using single-nucleus RNA sequencing and tissue clearing in a murine NASH model, we identified a repertoire of antifibrotic drug targets underlying advanced fibrosis, including an autocrine HSC signaling circuit composed of 68 receptor-ligand interactions conserved between murine and human NASH. Inhibiting one such autocrine interaction reversed advanced murine NASH fibrosis and inhibited human HSC activation in culture, suggesting the potential for stage-specific therapies in patients with advanced hepatic fibrosis.

SCIENCE TRANSLATIONAL MEDICINE (2023)

添加到收藏夹
Review Gastroenterology & Hepatology

Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD

Maral Amangurbanova et al.

Summary: The loss-of-function polymorphisms of HSD17B13 gene are associated with a reduced risk of NAFLD progression. Further understanding the mechanisms and utilizing this knowledge in the treatment of NAFLD is of great importance.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

添加到收藏夹
Article Biochemistry & Molecular Biology

Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches

Martin Guilliams et al.

Summary: This study presents a spatial proteogenomic atlas of the liver, combining multiple omics datasets, and reveals the cellular niches and transcriptomic identities of Kupffer cells and lipid-associated macrophages. It also demonstrates the inducibility of lipid-associated macrophages by local lipid exposure and the crucial role of ALK1-BMP9/10 axis in Kupffer cell development.

CELL (2022)

添加到收藏夹
Article Gastroenterology & Hepatology

Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis

Arun J. Sanyal et al.

Summary: The study aimed to assess the association between histologic and noninvasive tests with liver-related complications in NASH cirrhosis patients. The results showed that regression of fibrosis is associated with a reduction in liver-related complications.

HEPATOLOGY (2022)

添加到收藏夹
Article Gastroenterology & Hepatology

BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial

Eric J. Lawitz et al.

Summary: The study evaluated the efficacy and safety of BMS-986263 in treating advanced fibrosis in patients with HCV-SVR. Results showed improvements in METAVIR and Ishak scores with BMS-986263 treatment. Despite mild adverse events, overall tolerability was good.

HEPATOLOGY (2022)

添加到收藏夹
Review Biochemistry & Molecular Biology

The Potential Role of Cellular Senescence in Non-Alcoholic Fatty Liver Disease

Cornelius Engelmann et al.

Summary: Cellular senescence plays a significant role in non-alcoholic fatty liver disease (NAFLD), but further research is needed to understand the specific mechanisms. Hepatocyte senescence may contribute to fat accumulation, fibrosis, and inflammation, while senescence in non-parenchymal liver cells could potentially reduce fibrosis. A comprehensive understanding of the interaction between NAFLD and cellular senescence is crucial for identifying novel therapeutic targets.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

添加到收藏夹
Article Gastroenterology & Hepatology

A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH

David A. Fraser et al.

Summary: Comparative study between EPA and icosabutate shows that icosabutate has better resistance to oxidation and incorporation into hepatocytes, leading to reduced inflammation and fibrosis. Moreover, icosabutate shows hepatoprotective effects on mice and dyslipidaemic patients at risk of NASH.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹
Review Gastroenterology & Hepatology

Integrins as a drug target in liver fibrosis

Syedia R. Rahman et al.

Summary: As the prevalence of chronic liver diseases continues to rise, there is an urgent need for treatment to prevent cirrhosis-related morbidity and mortality. Integrins, specifically alpha v integrins, are promising targets for therapeutic intervention in the development of liver fibrosis. This review summarizes the current knowledge of alpha v integrins and their respective beta subunits in different organs, with a focus on liver fibrosis, and provides emerging preclinical and clinical data on alpha v integrin inhibitors.

LIVER INTERNATIONAL (2022)

添加到收藏夹
Review Gastroenterology & Hepatology

Neutrophils as potential therapeutic targets in hepatocellular carcinoma

Daniel Geh et al.

Summary: The success of atezolizumab plus bevacizumab treatment has led to a shift towards combination therapies in the treatment of hepatocellular carcinoma (HCC) that include cancer immunotherapies. The focus of cancer immunotherapy has primarily been on immune checkpoints, but emerging evidence supports the role of neutrophils as important contributors to the development and progression of HCC. Neutrophil-targeted therapies are now being explored in clinical trials and may have therapeutic benefits, including enhancing the effectiveness of conventional immunotherapy.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2022)

添加到收藏夹
Review Gastroenterology & Hepatology

Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology

Claudia D. Fuchs et al.

Summary: Bile acids play a crucial role in regulating metabolism and homeostasis, and their disrupted balance can contribute to gastrointestinal and liver diseases. Targeting bile acid pathways may provide novel treatment strategies for these disorders.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2022)

添加到收藏夹
Article Multidisciplinary Sciences

CAR T cells produced in vivo to treat cardiac injury

Joel G. Rurik et al.

Summary: This study developed a therapeutic approach to generate antifibrotic CAR T cells in vivo by delivering modified mRNA in T cell-targeted nanoparticles. The efficacy of these in vivo-reprogrammed CAR T cells was evaluated in a mouse model of heart failure.

SCIENCE (2022)

添加到收藏夹
Review Gastroenterology & Hepatology

Extracellular vesicles derived from mesenchymal stem/stromal cells: The regenerative impact in liver diseases

Adriana Psaraki et al.

Summary: Liver dysfunctions are often treated with liver transplantation, but a new concept in therapy involves using extracellular vesicles secreted by mesenchymal stem cells to overcome limitations and promote liver repair. Studies have shown that these vesicles have the potential to ameliorate systemic inflammation and positively impact various pathways associated with liver diseases.

HEPATOLOGY (2022)

添加到收藏夹
Editorial Material Gastroenterology & Hepatology

Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis

Rohit Loomba et al.

GASTROENTEROLOGY (2022)

添加到收藏夹
Article Biochemistry & Molecular Biology

Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease

Tobias Puengel et al.

Summary: Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are chronic liver diseases that can lead to end-stage liver disease and hepatocellular carcinoma (HCC) worldwide. The metabolic syndrome is closely linked to NAFLD, and comorbidities such as type 2 diabetes, obesity, and insulin resistance worsen liver disease, while NAFLD increases cardiovascular risk in affected patients. Therapeutic strategies targeting multiple drug targets or drugs with multiple mechanisms of actions are needed for effective treatment.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

添加到收藏夹
Article Gastroenterology & Hepatology

Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial

Naim Alkhouri et al.

Summary: This study evaluated the safety and efficacy of combining semaglutide with cilofexor and/or firsocostat in patients with NASH. The combination therapy was generally well tolerated and resulted in additional benefits over semaglutide monotherapy, including improvements in liver steatosis and biochemistry. Double-blind placebo-controlled trials with larger patient numbers are needed to further assess the efficacy and safety of these combination therapies in NASH.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹
Article Gastroenterology & Hepatology

Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease

Panu K. Luukkonen et al.

Summary: This study demonstrated that the mechanisms underlying the metabolic and genetic components of NAFLD are fundamentally different. The metabolic component is characterized by hepatic oversupply of substrates, while the genetic component is characterized by impaired hepatic mitochondrial function.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹
Review Gastroenterology & Hepatology

Promises of microbiome-based therapies

Jasmohan S. Bajaj et al.

Summary: This review discusses the importance of manipulating the gut microbiota as a novel treatment approach for liver diseases. It highlights the changes in intestinal microbiota and gut barrier dysfunction in patients with liver disease. Preclinical models demonstrate the significant role of gut microbiota in the pathogenesis of various liver diseases.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹
Review Gastroenterology & Hepatology

Breakthroughs in therapies for NASH and remaining challenges

Vlad Ratziu et al.

Summary: Nonalcoholic steatohepatitis (NASH) has become a leading cause of chronic liver disease, and the need for effective treatments is urgent. Recent breakthroughs and progress in understanding the pathogenesis have set the stage for future therapeutic successes in NASH.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹
Editorial Material Immunology

Culture amplified macrophages reassume identity and function in vivo

Michael H. Sieweke

Summary: Alveolar macrophages (AMs), which are resident macrophages of the lung, can be expanded ex vivo but may undergo epigenetic and transcriptional changes. However, when transplanted into mice lungs, culture-expanded AMs regain their in vivo identity and function.

NATURE IMMUNOLOGY (2022)

添加到收藏夹
Editorial Material Medicine, General & Internal

Fighting Cardiac Fibrosis with CAR T Cells

Scott L. Friedman

Summary: CAR-T cells, engineered to bind and kill specific antigen-expressing cells, have shown effectiveness in cancer treatment. A recent study in a mouse model suggests that CAR-T cells generated in vivo may also reduce fibrosis after myocardial injury.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹
Review Medicine, General & Internal

Alcohol-Associated Hepatitis

Ramon Bataller et al.

Summary: This article reviews the epidemiology, pathophysiology, and treatment of alcohol-associated hepatitis, including the evidence for glucocorticoids and liver transplantation.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹
Article Biochemistry & Molecular Biology

Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis

Tobias Puengel et al.

Summary: This study compared the effects of single drug and combination treatment as therapeutic strategies against non-alcoholic steatohepatitis (NASH). The results showed that CCR2/5 inhibition and FGF21 agonism both had favorable effects on improving NASH and fibrosis. Combination treatment amplified the beneficial effects and provided better outcomes in both short-term and long-term applications.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

添加到收藏夹
Review Gastroenterology & Hepatology

Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits

Moritz Peiseler et al.

Summary: Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease, and the immune system plays a significant role in different stages of NAFLD, with multiple inflammatory mechanisms involved. Recent research advancements have improved our understanding of the complex heterogeneity of liver immune cell subsets.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹
Article Gastroenterology & Hepatology

Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH

Nikolai V. V. Naoumov et al.

Summary: This study demonstrates that digital microscopy with artificial intelligence analyses has greater sensitivity in demonstrating treatment-induced reversal of fibrosis in the liver than current systems. Furthermore, additional details are obtained regarding the pathogenesis of NASH disease and the effects of therapy.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹
Article Biochemistry & Molecular Biology

Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study

Stephen A. Harrison et al.

Summary: In patients with nonalcoholic steatohepatitis (NASH), the use of licogliflozin led to reductions in serum alanine aminotransferase levels, suggesting it could be a potential therapeutic option. However, further studies are needed to validate these findings and evaluate its combination with other drugs.

NATURE MEDICINE (2022)

添加到收藏夹
Review Gastroenterology & Hepatology

Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update

Nicholas W. S. Chew et al.

Summary: Nonalcoholic steatohepatitis (NASH), a global health crisis, has spurred research on novel pharmacotherapies targeting metabolic pathways, cellular injury or inflammatory targets, liver-gut axis targets, and antifibrotic targets. This review summarizes therapeutic agents studied in phase 2 and 3 randomized trials and discusses the rationale behind combination therapy and lessons learned from unsuccessful trials.

SEMINARS IN LIVER DISEASE (2022)

添加到收藏夹
Review Endocrinology & Metabolism

Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis

Eva K. Wirth et al.

Summary: This review explores the role of thyroid hormone (TH) in regulating metabolism in the liver and the potential of targeting TH receptors (TRs) for the treatment of nonalcoholic fatty liver disease (NAFLD). Recent advances in drug development, particularly liver-targeted thyromimetics activating TR beta, offer new hope for effective therapies against NAFLD.

EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM (2022)

添加到收藏夹
Review Cell Biology

Gut-liver axis: Pathophysiological concepts and clinical implications

Herbert Tilg et al.

Summary: Bidirectional crosstalk between the gut and liver plays a crucial role in regulating gastrointestinal health and disease. Nutrients, microbial antigens, metabolites, and bile acids regulate metabolism and immune responses in the gut and liver, which reciprocally shape the structure and function of the microbial community. Perturbation of this host-microbe interaction is observed in various liver diseases and is exacerbated by impaired intestinal barrier, contributing to hepatic inflammation and disease progression.

CELL METABOLISM (2022)

添加到收藏夹
Review Pharmacology & Pharmacy

Spotlight on liver macrophages for halting injury and progression in nonalcoholic fatty liver disease

Tea Lund Laursen et al.

Summary: This review provides updates on recent studies of drugs that affect macrophages in NAFLD, both directly and indirectly, and discusses the implications of macrophage biomarkers in monitoring disease progression and regression.

EXPERT OPINION ON THERAPEUTIC TARGETS (2022)

添加到收藏夹
Article Biochemistry & Molecular Biology

Microbiome-derived ethanol in nonalcoholic fatty liver disease

Abraham S. Meijnikman et al.

Summary: This study found that microbial ethanol might contribute to pathogenesis in some patients with nonalcoholic fatty liver disease. The research suggests that microbial ethanol could be considered in the pathogenesis of this highly prevalent liver disease.

NATURE MEDICINE (2022)

添加到收藏夹
Review Gastroenterology & Hepatology

Metabolic Injury of Hepatocytes Promotes Progression of NAFLD and AALD

Raquel Carvalho-Gontijo et al.

Summary: Nonalcoholic liver disease is linked to metabolic syndrome and can lead to liver fibrosis. Chronic liver cell injury and death play a significant role in the development of liver fibrosis.

SEMINARS IN LIVER DISEASE (2022)

添加到收藏夹
Article Immunology

Long-term culture-expanded alveolar macrophages restore their full epigenetic identity after transfer in vivo

Sethuraman Subramanian et al.

Summary: Sieweke and colleagues demonstrate that alveolar macrophages maintain their core gene expression program even after long-term culture and regain their full transcriptional and epigenetic identity upon transplantation into the lung. This study shows that culture adaptations observed in ex vivo expanded alveolar macrophages are reversible and do not compromise their cellular identity in vivo. These findings provide new insights into the mechanisms of alveolar macrophages and highlight their therapeutic potential.

NATURE IMMUNOLOGY (2022)

添加到收藏夹
Review Immunology

Immune cell-mediated features of non-alcoholic steatohepatitis

Thierry Huby et al.

Summary: NASH is a serious chronic liver disorder with increasing prevalence globally. Metabolic disturbance and the role of immune cells are crucial in its onset and progression. Understanding the mechanisms by which immune cells contribute to NASH pathogenesis is essential for the development of innovative drugs targeting NASH.

NATURE REVIEWS IMMUNOLOGY (2022)

添加到收藏夹
Article Gastroenterology & Hepatology

Loss of hepatic Mboat7 leads to liver fibrosis

Veera Raghavan Thangapandi et al.

Summary: The rs641738C>T variant near the MBOAT7 locus is associated with liver fibrosis in various liver diseases. Mice with Mboat7 deficiency and human carriers of rs641738TT with fibrosis showed alterations in lipid signaling, suggesting a potential targetable treatment option for NAFLD.

GUT (2021)

添加到收藏夹
Review Immunology

Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities

Yankai Wen et al.

Summary: Macrophages, key cellular components of the liver, play essential roles in maintaining liver homeostasis, injury and repair processes in liver diseases. Kupffer cells and monocyte-derived macrophages contribute significantly to tissue inflammation and injury, but exhibit different functional responses in distinct liver diseases.

CELLULAR & MOLECULAR IMMUNOLOGY (2021)

添加到收藏夹
Review Pharmacology & Pharmacy

Role of microRNAs in Hepatic Stellate Cells and Hepatic Fibrosis: An Update

Sai Zhu et al.

Summary: MicroRNAs play vital roles in hepatic fibrosis, especially in the alteration of hepatic stellate cell phenotype. Abnormal expression of numerous miRNAs in activated HSCs could serve as potential novel biomarkers for HF treatment.

CURRENT PHARMACEUTICAL DESIGN (2021)

添加到收藏夹
Article Gastroenterology & Hepatology

Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort

Tracey G. Simon et al.

Summary: Population-based data in Sweden showed that all histological stages of NAFLD were linked with significantly increased overall mortality, and the risk escalated progressively with worsening histology. Excess mortality was mainly attributed to extrahepatic cancer and cirrhosis, while cardiovascular disease and HCC made modest contributions.

GUT (2021)

添加到收藏夹
Article Gastroenterology & Hepatology

The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in NASH

Rohit Loomba et al.

Summary: This study investigated the impact of aldafermin on the gut microbiota in patients with NASH. The results showed that aldafermin had a significant effect on the stability of the gut microbial community, leading to an enrichment in the rare genus Veillonella, which may be influenced by aldafermin-mediated suppression of bile acid synthesis.

HEPATOLOGY (2021)

添加到收藏夹
Review Gastroenterology & Hepatology

Cell therapy for advanced liver diseases: Repair or rebuild

Benjamin J. Dwyer et al.

Summary: Advanced liver disease poses a significant global health and economic burden, with liver transplantation as the only effective treatment option, but accompanied by risks and donor organ shortage. Cell therapies have advanced into early clinical trials, but challenges still need to be overcome before routine clinical use.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹
Review Gastroenterology & Hepatology

Maladaptive regeneration - the reawakening of developmental pathways in NASH and fibrosis

Changyu Zhu et al.

Summary: Emerging data suggest that the reactivation of developmental pathways is associated with nonalcoholic steatohepatitis (NASH) and fibrosis in the liver injury response. This review discusses the role of these pathways in liver development and in the pathogenesis of NASH and fibrosis.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)

添加到收藏夹
Review Gastroenterology & Hepatology

Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors

Sven Francque et al.

Summary: The global epidemic of obesity is associated with serious health consequences, including NAFLD, which can progress to liver fibrosis and cirrhosis. NAFLD is a systemic disease affecting multiple organs, with a complex pathomechanism involving PPARs as key regulators.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)

添加到收藏夹
Review Gastroenterology & Hepatology

Two Faces of Neutrophils in Liver Disease Development and Progression

Yeonhee Cho et al.

Summary: Neutrophils, the most abundant type of leukocyte in human blood, play a major role in host defense against invading pathogens and in sterile injury. However, under chronic inflammatory conditions, neutrophils may lose their self-resolving capabilities and maintain an inflammatory phenotype, exacerbating tissue damage. This review aims to provide a better understanding of how neutrophils interact with tissue microenvironments and acquire disease-specific phenotypes in various liver diseases.

HEPATOLOGY (2021)

添加到收藏夹
Review Pharmacology & Pharmacy

PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date

Alessandro Cherubini et al.

Summary: The interaction between metabolic triggers and inherited predisposition plays a crucial role in the development and progression of non-alcoholic fatty liver disease. Among specific NAFLD risk variants, the PNPLA3 rs738409 C>G variant is of significant interest due to its association with lipid accumulation, lipotoxicity, fibrosis, and carcinogenesis. Targeting PNPLA3 p.I148M could be a promising therapeutic approach for NAFLD progression.

EXPERT OPINION ON THERAPEUTIC TARGETS (2021)

添加到收藏夹
Article Cell Biology

Dynamic Shifts in the Composition of Resident and Recruited Macrophages Influence Tissue Remodeling in NASH

Sabine Daemen et al.

Summary: The study reveals that changes in liver macrophage subsets during the pathogenesis of NASH are dynamically linked to pathologic tissue remodeling. High-fat, high-sucrose-diet feeding leads to a decrease in mature TIM4(pos) Kupffer cells (KCs) and an accumulation of monocyte-derived Tim4(neg) macrophages in the liver. Additionally, C-LAMs expressing Cx3cr1/Ccr2 fail to appear in the liver in Ccr2-deficient mice, preventing the formation of hCLS and resulting in increased liver fibrosis.

CELL REPORTS (2021)

添加到收藏夹
Article Biochemistry & Molecular Biology

The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model

Philipp Schwabl et al.

Summary: Cilofexor, a non-steroidal FXR agonist, demonstrated a reduction in portal hypertension and liver fibrosis in experimental NASH. The combination with propranolol further decreased mesenteric hyperperfusion.

BIOMEDICINES (2021)

添加到收藏夹
Article Gastroenterology & Hepatology

Heterogeneity of HSCs in a Mouse Model of NASH

Sara Brin Rosenthal et al.

Summary: This study utilized single-cell RNA sequencing to characterize the phenotypic changes of hepatic stellate cells (HSCs) in a NASH model, revealing unexpected heterogeneity of HSC phenotypes under normal and injured states. The NASH livers showed four distinct HSC clusters, including one representing the classic fibrogenic myofibroblast, while livers with NASH regression had one cluster of inactivated HSCs similar to quiescent HSCs.

HEPATOLOGY (2021)

添加到收藏夹
Article Biochemistry & Molecular Biology

Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial

V. Ratziu et al.

Summary: Aramchol showed potential improvements in liver steatosis and fibrosis in NASH patients, but did not significantly reduce hepatic triglycerides. However, it demonstrated positive effects on liver histology and ALT levels in the clinical trial.

NATURE MEDICINE (2021)

添加到收藏夹
Article Biochemistry & Molecular Biology

ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials

Roberto A. Calle et al.

Summary: The study showed that ACC1/2 inhibitors had a good therapeutic effect in the treatment of non-alcoholic fatty liver disease, significantly reducing liver fat content. Co-administration of PF-05221304 and PF-06865571 can reduce the incidence of adverse events and mitigate the effect of ACC inhibition on serum triglycerides.

NATURE MEDICINE (2021)

添加到收藏夹
Article Medicine, General & Internal

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

Sven M. Francque et al.

Summary: In a randomized trial, the pan-PPAR agonist Lanifibranor showed significant improvement in histologic features of NASH at a dose of 1200 mg. However, adverse events such as weight gain, anemia, peripheral edema, diarrhea, and nausea were more common with Lanifibranor compared to placebo.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹
Article Medicine, General & Internal

Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease

Arun J. Sanyal et al.

Summary: In this study involving patients with nonalcoholic fatty liver disease, advanced fibrosis stages F3 and F4 were associated with increased risks of liver-related complications and death over a median of 4 years of follow-up. Advanced fibrosis was also related to an increased incidence of liver decompensation events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹
Review Gastroenterology & Hepatology

Targeting cell-intrinsic metabolism for antifibrotic therapy

Helene Gilgenkrantz et al.

Summary: Recent years have seen significant advances in understanding the mechanisms of fibrosis progression and regression, emphasizing the necessity of metabolic reprogramming to support the energetic and anabolic demands of cellular changes. Targeting cell-intrinsic metabolic modifications of key fibrogenic cells can impact fibrosis progression, and there is potential for antifibrogenic interventions targeting metabolism.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹
Review Pharmacology & Pharmacy

Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis

Atef Al Attar et al.

Summary: Gal-3 is a beta-galactoside binding protein associated with disease pathologies such as chronic inflammation and fibrogenesis, with ongoing studies investigating its role in NASH. Gal-3 inhibitors, particularly Belapectin, have shown promising results in NASH patients with advanced fibrosis, with further research aiming to replicate positive findings and demonstrate greater efficacy. If proven effective, Belapectin may be used in combination with other drugs targeting steatohepatitis for maximum efficacy and disease reversal.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2021)

添加到收藏夹
Review Immunology

Revisiting the Role of Natural Killer Cells in Non-Alcoholic Fatty Liver Disease

Maria Luz Martinez-Chantar et al.

Summary: NAFLD is the most common form of chronic liver disease, with NASH representing an advanced stage. NK cells play a key role in supporting hepatic inflammation in NASH, with research showing differential functions in different environments. Therapeutic approaches based on the modulation of NK cells show potential in managing NASH progression.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹
Review Biochemistry & Molecular Biology

Mechanisms and disease consequences of nonalcoholic fatty liver disease

Rohit Loomba et al.

Summary: NAFLD and NASH are leading chronic liver diseases worldwide, causing progressive liver injury that can lead to cirrhosis and hepatocellular carcinoma. These diseases are associated with hepatic glucose and lipid metabolism, and are influenced by genetic, epigenetic, and environmental factors.

CELL (2021)

添加到收藏夹
Review Gastroenterology & Hepatology

The Emerging Role of B Cells in the Pathogenesis of NAFLD

Fanta Barrow et al.

Summary: NAFLD is a leading cause of abnormal liver function globally, with inflammatory B cells playing a crucial role in the progression of the disease, potentially promoting disease development through the production of proinflammatory cytokines.

HEPATOLOGY (2021)

添加到收藏夹
Article Gastroenterology & Hepatology

Muscle fat content is strongly associated with NASH: a longitudinal study in patients with morbid obesity

Maxime Nachit et al.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹
Review Medicine, General & Internal

Non-alcoholic fatty liver disease

Elizabeth E. Powell et al.

Summary: Non-alcoholic fatty liver disease (NAFLD) is a common global health issue with significant associations with metabolic syndrome and type 2 diabetes, leading to serious complications like cirrhosis and hepatocellular carcinoma. While cardiovascular disease and extrahepatic malignancy are the main causes of death in NAFLD patients, advanced liver fibrosis is a key prognostic marker for liver-related outcomes and overall mortality.

LANCET (2021)

添加到收藏夹
Article Multidisciplinary Sciences

Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH

Michael Dudek et al.

Summary: Liver resident CD8 T cells play an essential role in immunopathology in a mouse model of nonalcoholic steatohepatitis. These cells display specific phenotypic and metabolic characteristics in the liver, making them susceptible to metabolic stimuli and leading to auto-aggressive responses. This study sheds light on the mechanisms underlying liver damage in NASH and highlights the distinction between auto-aggressive and protective T cell immunity.

NATURE (2021)

添加到收藏夹
Article Medicine, General & Internal

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

Philip N. Newsome et al.

Summary: This phase 2 trial demonstrated that treatment with semaglutide resulted in a significantly higher percentage of patients with NASH resolution compared to placebo in patients with NASH, but did not show a significant between-group difference in the percentage of patients with an improvement in fibrosis stage.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹
Review Gastroenterology & Hepatology

Systematic review and network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH

Abdul M. Majzoub et al.

Summary: This study evaluated the efficacy of different pharmacological interventions in improving liver fibrosis and NASH resolution, and provided ranking and probability of various drugs. The results showed that drugs like obeticholic acid and semaglutide demonstrated promising effects in the treatment of NASH.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)

添加到收藏夹
Article Biochemistry & Molecular Biology

Nuclear receptors in liver fibrosis

Philipp Koenigshofer et al.

Summary: Nuclear receptors play a crucial role in regulating gene expression involved in liver fibrosis, especially in hepatic stellate cells. Further research on nuclear receptors-related signaling may lead to the development of effective anti-fibrotic therapies for patients with liver disease.

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2021)

添加到收藏夹
Article Immunology

A subset of Kupffer cells regulates metabolism through the expression of CD36

Camille Bleriot et al.

Summary: The study shows that tissue macrophages in the murine liver (KCs) have more subpopulations, with one of them being associated with metabolic functions. Depletion of this subpopulation leads to increased liver oxidative stress, especially in obesity.

IMMUNITY (2021)

添加到收藏夹
Article Biochemistry & Molecular Biology

XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis

Aleksandra Deczkowska et al.

Summary: Single-cell analyses reveal cDC1 as conserved immunological drivers of non-alcoholic steatohepatitis in mice and humans. The study identified the significant role of cDC1 in NASH and confirmed their importance in liver pathology.

NATURE MEDICINE (2021)

添加到收藏夹
Review Immunology

Role of bile acids in inflammatory liver diseases

Ioannis Evangelakos et al.

Summary: Bile acids and their signaling pathways are potential therapeutic targets for cholestatic and metabolic liver diseases. New insights show that the interactions between bile acids and gut microbiome, as well as specific microbial bile acid metabolites, play crucial roles in immune regulation and liver disease modulation.

SEMINARS IN IMMUNOPATHOLOGY (2021)

添加到收藏夹
Article Multidisciplinary Sciences

CD8+ tissue-resident memory T cells promote liver fibrosis resolution by inducing apoptosis of hepatic stellate cells

Yuzo Koda et al.

Summary: The study identified CD8+ tissue-resident memory T cells as key players in resolving liver fibrosis, potentially through Fas-mediated cytotoxicity to eliminate hepatic stellate cells.

NATURE COMMUNICATIONS (2021)

添加到收藏夹
Review Gastroenterology & Hepatology

Molecular and cellular mechanisms of liver fibrosis and its regression

Tatiana Kisseleva et al.

Summary: Chronic liver injury results in liver inflammation and fibrosis, which can be reversed by eliminating activated myofibroblasts and resorbing the fibrous scar. Understanding the molecular mechanisms underlying liver fibrosis and its reversibility can lead to the identification of new therapeutic targets for liver fibrosis treatment.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)

添加到收藏夹
Article Gastroenterology & Hepatology

Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis

Oliver Krenkel et al.

GUT (2020)

添加到收藏夹
Review Gastroenterology & Hepatology

The gut-liver axis in liver disease: Pathophysiological basis for therapy

Agustin Albillos et al.

JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹
Article Multidisciplinary Sciences

An acute immune response underlies the benefit of cardiac stem cell therapy

Ronald J. Vagnozzi et al.

NATURE (2020)

添加到收藏夹
Review Gastroenterology & Hepatology

Adaptive immunity: an emerging player in the progression of NAFLD

Salvatore Sutti et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)

添加到收藏夹
Article Gastroenterology & Hepatology

Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension

Naga Chalasani et al.

GASTROENTEROLOGY (2020)

添加到收藏夹
Article Gastroenterology & Hepatology

Mechanisms of Fibrosis Development in NASH

Robert F. Schwabe et al.

GASTROENTEROLOGY (2020)

添加到收藏夹
Article Gastroenterology & Hepatology

Adipose Tissue-Liver Cross Talk in the Control of Whole-Body Metabolism: Implications in Nonalcoholic Fatty Liver Disease

Vian Azzu et al.

GASTROENTEROLOGY (2020)

添加到收藏夹
Article Gastroenterology & Hepatology

Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study

Vlad Ratziu et al.

HEPATOLOGY (2020)

添加到收藏夹
Review Gastroenterology & Hepatology

Update on NAFLD genetics: From new variants to the clinic

Eric Trepo et al.

JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹
Article Gastroenterology & Hepatology

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison et al.

JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹
Article Multidisciplinary Sciences

SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis

Jiyu Zhou et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹
Article Gastroenterology & Hepatology

Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data

Rohit Loomba et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)

添加到收藏夹
Review Gastroenterology & Hepatology

Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis

Bjorn Carlsson et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)

添加到收藏夹
Article Immunology

Niche-Specific Reprogramming of Epigenetic Landscapes Drives Myeloid Cell Diversity in Nonalcoholic Steatohepatitis

Jason S. Seidman et al.

IMMUNITY (2020)

添加到收藏夹
Article Gastroenterology & Hepatology

Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis

Jinhang Gao et al.

JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹
Article Gastroenterology & Hepatology

Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages

Sander Lefere et al.

JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹
Article Gastroenterology & Hepatology

Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation

Jamie Bates et al.

JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹
Review Gastroenterology & Hepatology

Single-cell technologies in hepatology: new insights into liver biology and disease pathogenesis

Prakash Ramachandran et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)

添加到收藏夹
Article Gastroenterology & Hepatology

Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis

Guillaume Lassailly et al.

GASTROENTEROLOGY (2020)

添加到收藏夹
Article Immunology

Impaired Kupffer Cell Self-Renewal Alters the Liver Response to Lipid Overload during Non-alcoholic Steatohepatitis

Sophie Tran et al.

IMMUNITY (2020)

添加到收藏夹
Article Gastroenterology & Hepatology

Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems

Trenton T. Ross et al.

CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2020)

添加到收藏夹
Article Multidisciplinary Sciences

Senolytic CAR T cells reverse senescence-associated pathologies

Corina Amor et al.

NATURE (2020)

添加到收藏夹
Review Gastroenterology & Hepatology

The NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis

Jana Knorr et al.

SEMINARS IN LIVER DISEASE (2020)

添加到收藏夹
Article Immunology

Osteopontin Expression Identifies a Subset of Recruited Macrophages Distinct from Kupffer Cells in the Fatty Liver

Anneleen Remmerie et al.

IMMUNITY (2020)

添加到收藏夹
Review Multidisciplinary Sciences

Fibrosis: from mechanisms to medicines

Neil C. Henderson et al.

NATURE (2020)

添加到收藏夹
Letter Oncology

Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions

Li Zhang et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

添加到收藏夹
Review Immunology

Thymic development of unconventional T cells: how NKT cells, MAIT cells and γδ T cells emerge

Daniel G. Pellicci et al.

NATURE REVIEWS IMMUNOLOGY (2020)

添加到收藏夹
Article Endocrinology & Metabolism

Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis

Michelle L. Boland et al.

NATURE METABOLISM (2020)

添加到收藏夹
Article Biochemistry & Molecular Biology

Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer

Mohsen Malehmir et al.

NATURE MEDICINE (2019)

添加到收藏夹
Article Cell Biology

Single Cell RNA Sequencing Identifies Subsets of Hepatic Stellate Cells and Myofibroblasts in Liver Fibrosis

Oliver Krenkel et al.

CELLS (2019)

添加到收藏夹
Article Engineering, Biomedical

Liver fibrosis affects the targeting properties of drug delivery systems to macrophage subsets in vivo

Can Ergen et al.

BIOMATERIALS (2019)

添加到收藏夹
Article Biochemistry & Molecular Biology

Lipid-Associated Macrophages Control Metabolic Homeostasis in a Trem2-Dependent Manner

Diego Adhemar Jaitin et al.

CELL (2019)

添加到收藏夹
Review Gastroenterology & Hepatology

Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD

Mary E. Rinella et al.

JOURNAL OF HEPATOLOGY (2019)

添加到收藏夹
Article Medicine, Research & Experimental

Neutrophils contribute to spontaneous resolution of liver inflammation and fibrosis via microRNA-223

Carolina Jimenez Calvente et al.

JOURNAL OF CLINICAL INVESTIGATION (2019)

添加到收藏夹
Article Multidisciplinary Sciences

Resolving the fibrotic niche of human liver cirrhosis at single-cell level

P. Ramachandran et al.

NATURE (2019)

添加到收藏夹
Article Biochemistry & Molecular Biology

Safety profile of autologous macrophage therapy for liver cirrhosis

Francesca Moroni et al.

NATURE MEDICINE (2019)

添加到收藏夹
Article Cell Biology

Single-Cell Transcriptomics Uncovers Zonation of Function in the Mesenchyme during Liver Fibrosis

Ross Dobie et al.

CELL REPORTS (2019)

添加到收藏夹
Review Gastroenterology & Hepatology

The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

Konstantin Kazankov et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)

添加到收藏夹
Article Medicine, General & Internal

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi et al.

LANCET (2019)

添加到收藏夹
Review Immunology

Mucosal-associated invariant T cells and disease

Amine Toubal et al.

NATURE REVIEWS IMMUNOLOGY (2019)

添加到收藏夹
Article Endocrinology & Metabolism

Transcriptional network analysis implicates altered hepatic immune function in NASH development and resolution

Joel T. Haas et al.

NATURE METABOLISM (2019)

添加到收藏夹
Article Gastroenterology & Hepatology

PNPLA3 I148M Variant Impairs Liver X Receptor Signaling and Cholesterol Homeostasis in Human Hepatic Stellate Cells

Francesca Virginia Bruschi et al.

HEPATOLOGY COMMUNICATIONS (2019)

添加到收藏夹
Review Cell Biology

Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases

Varman T. Samuel et al.

CELL METABOLISM (2018)

添加到收藏夹
Article Gastroenterology & Hepatology

Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis

Stephen A. Harrison et al.

GASTROENTEROLOGY (2018)

添加到收藏夹
Article Gastroenterology & Hepatology

Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study

Eduardo Vilar-Gomez et al.

GASTROENTEROLOGY (2018)

添加到收藏夹
Article Gastroenterology & Hepatology

Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis

Oliver Krenkel et al.

HEPATOLOGY (2018)

添加到收藏夹
Article Gastroenterology & Hepatology

MAIT cells are chronically activated in patients with autoimmune liver disease and promote profibrogenic hepatic stellate cell activation

Katrin Bottcher et al.

HEPATOLOGY (2018)

添加到收藏夹
Review Medicine, Research & Experimental

Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators

Charles N. Serhan et al.

JOURNAL OF CLINICAL INVESTIGATION (2018)

添加到收藏夹
Review Biotechnology & Applied Microbiology

Targeting the NLRP3 inflammasome in inflammatory diseases

Matthew S. J. Mangan et al.

NATURE REVIEWS DRUG DISCOVERY (2018)

添加到收藏夹
Article Multidisciplinary Sciences

Mucosal-associated invariant T cells are a profibrogenic immune cell population in the liver

Pushpa Hegde et al.

NATURE COMMUNICATIONS (2018)

添加到收藏夹
Review Biochemistry & Molecular Biology

Innate Lymphoid Cells: 10 Years On

Eric Vivier et al.

CELL (2018)

添加到收藏夹
Article Multidisciplinary Sciences

Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations

Sonya A. MacParland et al.

NATURE COMMUNICATIONS (2018)

添加到收藏夹
Review Immunology

Adapted Immune Responses of Myeloid-Derived Cells in Fatty Liver Disease

Jana Hundertmark et al.

FRONTIERS IN IMMUNOLOGY (2018)

添加到收藏夹
Article Gastroenterology & Hepatology

Stearoyl-CoA Desaturase Promotes Liver Fibrosis and Tumor Development in Mice via a Wnt Positive-Signaling Loop by Stabilization of Low-Density Lipoprotein-Receptor-Related Proteins 5 and 6

Keane K. Y. Lai et al.

GASTROENTEROLOGY (2017)

添加到收藏夹
Article Gastroenterology & Hepatology

The PNPLA3 I148M Variant Modulates the Fibrogenic Phenotype of Human Hepatic Stellate Cells

Francesca Virginia Bruschi et al.

HEPATOLOGY (2017)

添加到收藏夹
Review Gastroenterology & Hepatology

Increased Risk of Mortality by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis

Parambir S. Dulai et al.

HEPATOLOGY (2017)

添加到收藏夹
Review Gastroenterology & Hepatology

Targeting hepatic macrophages to treat liver diseases

Frank Tacke

JOURNAL OF HEPATOLOGY (2017)

添加到收藏夹
Article Gastroenterology & Hepatology

Cytotherapy with M1-polarized macrophages ameliorates liver fibrosis by modulating immune microenvironment in mice

Peng-Fei Ma et al.

JOURNAL OF HEPATOLOGY (2017)

添加到收藏夹
Article Gastroenterology & Hepatology

Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD

Hannes Hagstrom et al.

JOURNAL OF HEPATOLOGY (2017)

添加到收藏夹
Review Biochemistry & Molecular Biology

An emerging role for neutrophil extracellular traps in noninfectious disease

Selina K. Jorch et al.

NATURE MEDICINE (2017)

添加到收藏夹
Review Gastroenterology & Hepatology

Mechanisms of hepatic stellate cell activation

Takuma Tsuchida et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2017)

添加到收藏夹
Review Gastroenterology & Hepatology

Macrophages in Nonalcoholic Fatty Liver Disease: A Role Model of Pathogenic Immunometabolism

Oliver Krenkel et al.

SEMINARS IN LIVER DISEASE (2017)

添加到收藏夹
Review Immunology

Liver macrophages in tissue homeostasis and disease

Oliver Krenkel et al.

NATURE REVIEWS IMMUNOLOGY (2017)

添加到收藏夹
Article Immunology

Adipose-Resident Group 1 Innate Lymphoid Cells Promote Obesity-Associated Insulin Resistance

Timothy E. O'Sullivan et al.

IMMUNITY (2016)

添加到收藏夹
Review Gastroenterology & Hepatology

Immunology in the liver - from homeostasis to disease

Felix Heymann et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2016)

添加到收藏夹
Review Pharmacology & Pharmacy

Pharmacological Intervention in Hepatic Stellate Cell Activation and Hepatic Fibrosis

Hans-Theo Schon et al.

FRONTIERS IN PHARMACOLOGY (2016)

添加到收藏夹
Article Gastroenterology & Hepatology

Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies

Siddharth Singh et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)

添加到收藏夹
Editorial Material Gastroenterology & Hepatology

Hepatology Snapshot: Mechanisms of liver fibrosis resolution

Frank Tacke et al.

JOURNAL OF HEPATOLOGY (2015)

添加到收藏夹
Article Genetics & Heredity

A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis

Stephan Buch et al.

NATURE GENETICS (2015)

添加到收藏夹
Article Multidisciplinary Sciences

Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity

Jonathan R. Brestoff et al.

NATURE (2015)

添加到收藏夹
Article Oncology

Metabolic Activation of lntrahepatic CD8+ T Cells and NKT Cells Causes Nonalcoholic Steatohepatitis and Liver Cancer via Cross-Talk with Hepatocytes

Monika Julia Wolf et al.

CANCER CELL (2014)

添加到收藏夹
Review Gastroenterology & Hepatology

Roles for Chemokines in Liver Disease

Fabio Marra et al.

GASTROENTEROLOGY (2014)

添加到收藏夹
Article Gastroenterology & Hepatology

Pharmacological Inhibition of the Chemokine C-C Motif Chemokine Ligand 2 (Monocyte Chemoattractant Protein 1) Accelerates Liver Fibrosis Regression by Suppressing Ly-6C+ Macrophage Infiltration in Mice

Christer Baeck et al.

HEPATOLOGY (2014)

添加到收藏夹
Article Gastroenterology & Hepatology

A TLR2/S100A9/CXCL-2 signaling network is necessary for neutrophil recruitment in acute and chronic liver injury in the mouse

Anna Moles et al.

JOURNAL OF HEPATOLOGY (2014)

添加到收藏夹
Review Immunology

Liver fibrosis and repair: immune regulation of wound healing in a solid organ

Antonella Pellicoro et al.

NATURE REVIEWS IMMUNOLOGY (2014)

添加到收藏夹
Article Immunology

Chemokine Receptor CXCR6-Dependent Hepatic NK T Cell Accumulation Promotes Inflammation and Liver Fibrosis

Alexander Wehr et al.

JOURNAL OF IMMUNOLOGY (2013)

添加到收藏夹
Review Immunology

Immune surveillance by the liver

Craig N. Jenne et al.

NATURE IMMUNOLOGY (2013)

添加到收藏夹
Article Biochemistry & Molecular Biology

Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs

Neil C. Henderson et al.

NATURE MEDICINE (2013)

添加到收藏夹
Article Gastroenterology & Hepatology

Autophagy Releases Lipid That Promotes Fibrogenesis by Activated Hepatic Stellate Cells in Mice and in Human Tissues

Virginia Hernandez-Gea et al.

GASTROENTEROLOGY (2012)

添加到收藏夹
Article Gastroenterology & Hepatology

NKp46-mediated killing of human and mouse hepatic stellate cells attenuates liver fibrosis

Chamutal Gur et al.

GUT (2012)

添加到收藏夹
Article Gastroenterology & Hepatology

NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease

Wing-Kin Syn et al.

GUT (2012)

添加到收藏夹
Article Gastroenterology & Hepatology

Macrophage Therapy for Murine Liver Fibrosis Recruits Host Effector Cells Improving Fibrosis, Regeneration, and Function

James A. Thomas et al.

HEPATOLOGY (2011)

添加到收藏夹
Article Gastroenterology & Hepatology

A role for autophagy during hepatic stellate cell activation

Lien F. R. Thoen et al.

JOURNAL OF HEPATOLOGY (2011)

添加到收藏夹
研讨会 海报 问题 讨论圈 基金 期刊 论文 科研社交 资讯集成 审稿人 关于我们 常见问题 移动App 隐私条款 使用条款
© Peeref 2019-2024. All rights reserved.